What is the optimal treatment for an adult with psoriasis, considering disease severity?

Best Treatment for Psoriasis

For mild-to-moderate psoriasis, start with combination topical therapy using calcipotriene plus betamethasone dipropionate; for moderate-to-severe psoriasis, initiate biologic therapy with IL-17 inhibitors (bimekizumab or ixekizumab) or IL-23 inhibitors (risankizumab or guselkumab) as first-line systemic treatment. 1, 2

Treatment Algorithm by Disease Severity

Mild-to-Moderate Psoriasis (<10% BSA)

Topical therapy is the foundation of treatment:

• First-line: Calcipotriene 0.005% plus betamethasone dipropionate 0.064% combination product applied once or twice daily 1

  • This combination is more effective than either agent alone
  • Can be used safely for up to 52 weeks without significant adverse events including striae or HPA axis suppression
  • 69-74% of patients achieve clear or almost clear status

• For scalp psoriasis: Calcipotriene foam or calcipotriene plus betamethasone dipropionate gel for 4-12 weeks 1

  • Calcipotriene foam achieves 40.9% clear/almost clear at 8 weeks versus 24.2% with vehicle

• For facial psoriasis: Calcipotriene or tacalcitol combined with hydrocortisone for 8 weeks 1

  • Hydrocortisone-containing formulations are more effective on facial skin (OR 2.01)

Moderate-to-Severe Psoriasis (≥10% BSA or high-impact areas)

Biologic therapy should be initiated as first-line systemic treatment based on the most recent evidence:

First-Line Biologic Options (in order of efficacy for PASI 90):

1. Bimekizumab (IL-17 inhibitor) - Highest efficacy with high-certainty evidence 2

   • Loading: 320 mg at weeks 0,4,8,12,16
   • Maintenance: 320 mg every 4 weeks

2. Ixekizumab (IL-17 inhibitor) - Moderate-certainty evidence 2

   • Loading: 160 mg at week 0, then 80 mg at weeks 2,4,6,8,10,12
   • Maintenance: 80 mg every 4 weeks

3. Risankizumab (IL-23 inhibitor) - Moderate-certainty evidence, longer dosing intervals 2, 3

   • Loading: 150 mg at weeks 0 and 4
   • Maintenance: 150 mg every 12 weeks

4. Guselkumab (IL-23 inhibitor) - Durable responses 4

   • Loading: 100 mg at weeks 0 and 4
   • Maintenance: 100 mg every 8 weeks

5. Secukinumab (IL-17 inhibitor) 5

   • Loading: 300 mg at weeks 0,1,2,3,4
   • Maintenance: 300 mg every 4 weeks
   • 300 mg dose is more effective than 150 mg

Alternative First-Line Options When Biologics Are Not Available:

Methotrexate is recommended when cost or availability limits biologic access 4, 6

• Start 7.5-15 mg weekly, titrate to 25 mg weekly
• Requires monitoring: CBC, CMP, hepatitis B/C screening before initiation

Special Considerations

Psoriatic Arthritis

TNF-alpha inhibitors remain preferred when psoriatic arthritis is present 5:

• Adalimumab: 80 mg initial dose, then 40 mg at week 1, then 40 mg every 2 weeks 5
• Infliximab: 5 mg/kg at weeks 0,2,6, then every 8 weeks 5
  • Consider adding methotrexate to reduce immunogenicity and maintain response
• TNF inhibitors have established efficacy for preventing radiographic joint damage

High-Impact Sites

Nail psoriasis:

• Adalimumab (Strength A) 5
• Secukinumab (Strength A) 5
• Ustekinumab (Strength B) 5

Palmoplantar psoriasis:

• Secukinumab 300 mg (Strength A) 5
• Adalimumab (Strength A) 5
• Ustekinumab 90 mg for patients >100 kg (Strength B) 5

Scalp psoriasis:

• Topical: Calcipotriene plus betamethasone gel (Strength A) 1
• Systemic: Secukinumab (Strength B) 5

Cardiovascular Risk Factors

TNF inhibitors are preferred in patients with cardiovascular comorbidities 4

Inflammatory Bowel Disease

Avoid IL-17 inhibitors - increased risk of IBD exacerbation or new-onset IBD 3 Prefer: Ustekinumab or IL-23 inhibitors

Treatment Goals

Minimum acceptable target: PASI 75 response 7 Optimal target: PASI 90 or absolute PASI <2 7

Assess response at 12-16 weeks for biologics, 8-12 weeks for conventional systemics.

Common Pitfalls

1. Vitamin D analogues and phototherapy: Apply calcipotriene AFTER phototherapy to avoid UVA inactivation and UVB blocking 1

2. Infliximab intervals: Do not extend beyond 8 weeks - increases immunogenicity and infusion reactions 5

3. IL-17 inhibitors: Monitor for mucocutaneous candidiasis 3

4. Methotrexate with infliximab: Strongly consider combination to reduce antibody formation and maintain efficacy 5

Inadequate Response Strategy

If insufficient response at 12-16 weeks:

• Dose escalation: Increase frequency (e.g., ustekinumab every 8 weeks instead of 12) 5
• Switch within class: Change to different IL-17 or IL-23 inhibitor
• Switch between classes: Move from TNF-alpha to IL-17/IL-23 or vice versa
• Add topical therapy: High-potency corticosteroid with vitamin D analogue 1

The evidence strongly supports IL-17 and IL-23 inhibitors as superior first-line biologics over older TNF-alpha inhibitors and IL-12/23 inhibitors for achieving complete or near-complete skin clearance 2, 4. However, TNF inhibitors retain specific advantages for psoriatic arthritis and cardiovascular disease 5, 4.